Jiang T, Tang G, Lin Y, Peng X, Zhang X, Zhai X, et al. Prevalence estimates for primary brain tumors in China: a multi-center cross-sectional study. Chin Med J. 2011;124:2578–83.

PubMed  Google Scholar 

Collaborators G 2016 B and OCC, Patel AP, Fisher JL, Nichols E, Abd-Allah F, Abdela J, et al. Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:376–93.

Article  Google Scholar 

Johnson KC, Anderson KJ, Courtois ET, Gujar AD, Barthel FP, Varn FS, et al. Single-cell multimodal glioma analyses identify epigenetic regulators of cellular plasticity and environmental stress response. Nat Genet. 2021;53:1456–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bready D, Placantonakis DG. Molecular pathogenesis of low-grade glioma. Neurosurg Clin North Am. 2019;30:17–25.

Article  Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World health organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.

Article  PubMed  Google Scholar 

Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults. JAMA. 2023;329:574–87.

Article  PubMed  Google Scholar 

Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Network CGAR, Brat DJ, Verhaak RGW, Aldape KD, Yung WKA, Salama SR, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481–98.

Article  Google Scholar 

Song L-R, Weng J-C, Li C-B, Huo X-L, Li H, Hao S-Y, et al. Prognostic and predictive value of an immune infiltration signature in diffuse lower-grade gliomas. JCI Insight. 2020;5: e133811.

Article  PubMed  PubMed Central  Google Scholar 

Smits A, Jakola AS. Clinical presentation, natural history, and prognosis of diffuse low-grade gliomas. Neurosurg Clin North Am. 2019;30:35–42.

Article  Google Scholar 

Chen H, Li M, Guo Y, Zhong Y, He Z, Xu Y, et al. Immune response in glioma’s microenvironment. Innov Surg Sci. 2021;5:115–25.

PubMed Central  Google Scholar 

Zhao Z, Zhang K-N, Wang Q, Li G, Zeng F, Zhang Y, et al. Chinese glioma genome atlas (CGGA): a comprehensive resource with functional genomic data from Chinese glioma patients. Genom Proteom Bioinform. 2021;19:1–12.

Article  CAS  Google Scholar 

Khan F, Pang L, Dunterman M, Lesniak MS, Heimberger AB, Chen P. Macrophages and microglia in glioblastoma: heterogeneity, plasticity, and therapy. J Clin Investig. 2023;133: e163446.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bikfalvi A, da Costa CA, Avril T, Barnier J-V, Bauchet L, Brisson L, et al. Challenges in glioblastoma research: focus on the tumor microenvironment. Trends Cancer. 2023;9:9–27.

Article  CAS  PubMed  Google Scholar 

Barthel L, Hadamitzky M, Dammann P, Schedlowski M, Sure U, Thakur BK, et al. Glioma: molecular signature and crossroads with tumor microenvironment. Cancer Metastasis Rev. 2022;41:53–75.

Article  CAS  PubMed  Google Scholar 

Ochocka N, Segit P, Walentynowicz KA, Wojnicki K, Cyranowski S, Swatler J, et al. Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages. Nat Commun. 2021;12:1151.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Andersen RS, Anand A, Harwood DSL, Kristensen BW. Tumor-associated microglia and macrophages in the glioblastoma microenvironment and their implications for therapy. Cancers. 2021;13:4255.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hara T, Chanoch-Myers R, Mathewson ND, Myskiw C, Atta L, Bussema L, et al. Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma. Cancer Cell. 2021;39:779-792.e11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boutilier AJ, Elsawa SF. Macrophage polarization states in the tumor microenvironment. Int J Mol Sci. 2021;22:6995.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ravi VM, Neidert N, Will P, Joseph K, Maier JP, Kückelhaus J, et al. T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nat Commun. 2022;13:925.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Papadopoulos KP, Gluck L, Martin LP, Olszanski AJ, Tolcher AW, Ngarmchamnanrith G, et al. First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors. Clin Cancer Res. 2017;23:5703–10.

Article  CAS  PubMed  Google Scholar 

Butowski N, Colman H, Groot JFD, Omuro AM, Nayak L, Wen PY, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy foundation early phase clinical trials consortium phase II study. Neuro-Oncol. 2016;18:557–64.

Article  PubMed  Google Scholar 

O’Brien SA, Orf J, Skrzypczynska KM, Tan H, Kim J, DeVoss J, et al. Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment. Cancer Immunol Immunother. 2021;70:2401–10.

Article  PubMed  PubMed Central  Google Scholar 

Ma R-Y, Black A, Qian B-Z. Macrophage diversity in cancer revisited in the era of single-cell omics. Trends Immunol. 2022;43:546–63.

Article  CAS  PubMed  Google Scholar 

Abdelfattah N, Kumar P, Wang C, Leu J-S, Flynn WF, Gao R, et al. Single-cell analysis of human glioma and immune cells identifies S100A4 as an immunotherapy target. Nat Commun. 2022;13:767.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Antunes ARP, Scheyltjens I, Lodi F, Messiaen J, Antoranz A, Duerinck J, et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat Neurosci. 2021;24:595–610.

Article  Google Scholar 

Alban TJ, Alvarado AG, Sorensen MD, Bayik D, Volovetz J, Serbinowski E, et al. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight. 2018;3: e122264.

Article  PubMed  PubMed Central  Google Scholar 

Prosniak M, Harshyne LA, Andrews DW, Kenyon LC, Bedelbaeva K, Apanasovich TV, et al. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res. 2013;19:3776–86.

Article  CAS  PubMed  Google Scholar 

Pinton L, Masetto E, Vettore M, Solito S, Magri S, D’Andolfi M, et al. The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. J Immunother Cancer. 2019;7:58.

Article  PubMed  PubMed Central  Google Scholar 

Saxena M, van der Burg SH, Melief CJM, Bhardwaj N. Therapeutic cancer vaccines. Nat Rev Cancer. 2021;21:360–78.

Article  CAS  PubMed  Google Scholar 

Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359:1350–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, et al. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: an international randomized phase III trial. Neuro-Oncol. 2022;25:123–34.

Article  PubMed Central  Google Scholar 

Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, et al. Effect of nivolumab vs. bevacizumab in patients with recurrent glioblastoma. JAMA Oncol. 2020;6:1003–10.

Article  PubMed  Google Scholar 

Lim M, Weller M, Idbaih A, Steinbach J, Finocchiaro G, Raval RR, et al. Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter. Neuro-Oncol. 2022;24:1935–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019;565:240–5.

Article  CAS  PubMed  Google Scholar 

Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565:234–9.

Article